These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38921459)

  • 1. Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective.
    Baffy G; Portincasa P
    Metabolites; 2024 Jun; 14(6):. PubMed ID: 38921459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Benedé-Ubieto R; Cubero FJ; Nevzorova YA
    Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.
    Jaeger JW; Brandt A; Gui W; Yergaliyev T; Hernández-Arriaga A; Muthu MM; Edlund K; Elashy A; Molinaro A; Möckel D; Sarges J; Halibasic E; Trauner M; Kahles F; Rolle-Kampczyk U; Hengstler J; Schneider CV; Lammers T; Marschall HU; von Bergen M; Camarinha-Silva A; Bergheim I; Trautwein C; Schneider KM
    JHEP Rep; 2024 Mar; 6(3):100987. PubMed ID: 38328439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
    Lu X; Yang R; Chen Y; Chen D
    iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
    Gabbia D; De Martin S
    Biology (Basel); 2023 Nov; 12(12):. PubMed ID: 38132297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and portal hypertension.
    Ryou M; Stylopoulos N; Baffy G
    Explor Med; 2020; 1():149-169. PubMed ID: 32685936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8
    Zheng C; Wang L; Zou T; Lian S; Luo J; Lu Y; Hao H; Xu Y; Xiang Y; Zhang X; Xu G; Zou X; Jiang R
    J Hepatol; 2024 May; 80(5):764-777. PubMed ID: 38181823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.
    Baffy G
    Dig Dis Sci; 2018 Mar; 63(3):563-576. PubMed ID: 29368124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
    Paternostro R; Kwanten WJ; Hofer BS; Semmler G; Bagdadi A; Luzko I; Hernández-Gea V; Graupera I; García-Pagán JC; Saltini D; Indulti F; Schepis F; Moga L; Rautou PE; Llop E; Téllez L; Albillos A; Fortea JI; Puente A; Tosetti G; Primignani M; Zipprich A; Vuille-Lessard E; Berzigotti A; Taru MG; Taru V; Procopet B; Jansen C; Praktiknjo M; Gu W; Trebicka J; Ibanez-Samaniego L; Bañares R; Rivera-Esteban J; Pericas JM; Genesca J; Alvarado E; Villanueva C; Larrue H; Bureau C; Laleman W; Ardevol A; Masnou H; Vanwolleghem T; Trauner M; Mandorfer M; Francque S; Reiberger T;
    J Hepatol; 2024 May; ():. PubMed ID: 38823501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A narrative review about cognitive impairment in metabolic Dysfunction-Associated liver disease (MASLD): Another matter to face through a holistic approach.
    Meroni M; Longo M; Paolini E; Dongiovanni P
    J Adv Res; 2024 Feb; ():. PubMed ID: 38369241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
    Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
    Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
    Martínez-Sanz J; Talavera-Rodríguez A; Díaz-Álvarez J; Rosas Cancio-Suárez M; Rodríguez JM; Alba C; Montes ML; Martín-Mateos R; Burgos-Santamaría D; Moreno S; Serrano-Villar S; Sánchez-Conde M
    Front Immunol; 2023; 14():1297378. PubMed ID: 38162648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.